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Background. Benign prostatic hyperplasia (BPH) and
chronic kidney disease are important public health problems in
older men. Previous referral-based studies disagree on whether
BPH is associated with chronic kidney disease. The objective
of this study was to determine the community-based associ-
ation between clinical measures of BPH and chronic kidney
disease.
Methods. A community-based sample of 2115 white men
(ages 40–79 years) was randomly selected from the Olm-
sted County, Minnesota population (55% participation rate)
in 1990. A random subsample (N = 476) had a detailed
clinical evaluation. This evaluation included a questionnaire
with similar queries to the International Prostate Symptom
Score (IPSS), peak urinary flow rates (uroflowmeter), postvoid
residual urine volume (ultrasound), prostate volume (ultra-
sound), serum prostate specific antigen (PSA), and serum
creatinine.
Results. After adjustment for age, hypertension, diabetes,
leukocyte esterase positive (possible urinary tract infection),
and smoking, chronic kidney disease [serum creatinine ≥133
lmol/L (1.5 mg/dL)] was associated with diminished peak uri-
nary flow rate (<15 mL/sec) by an odds ratio (OR) = 2.96 (95%
CI 1.30–7.01), moderate-severe lower urinary tract symptoms
(IPSS >7) by an OR = 2.91 (95% CI 1.32–6.62), and chronic
urinary retention (postvoid residual >100 mL) by an OR = 2.28
(95% CI 0.66–6.68). There was no association with a prostate
volume >30 mL by an OR = 0.56 (95% CI 0.22–1.37) or PSA
>1.4 ng/mL by an OR = 1.17 (95% CI 0.47–2.81).
Conclusion. There was a cross-sectional association between
signs and symptoms of bladder outlet obstruction and chronic
kidney disease in community-dwelling men. Prostatic enlarge-
ment was not associated with chronic kidney disease.
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Chronic kidney disease is an important public health
problem, especially in older men. Approximately 11%
of adults have chronic kidney disease according to data
from the third National Health and Nutrition Examina-
tion Survey (NHANES III) [1]. Men have 67% more
incident advanced chronic kidney disease than women
after adjusting for age, cigarette smoking, and diabetes
[2]. Identified risk factors for chronic kidney disease in-
clude diabetes, hypertension, smoking, obesity, dyslipi-
demia, and metabolic syndrome [3, 4]. Adverse outcomes
of chronic kidney disease include end-stage renal disease,
cardiovascular disease, and premature death. The best
way to prevent these adverse outcomes may be to iden-
tify and treat chronic kidney disease risk factors [5].
One possible risk factor for chronic kidney disease may
be benign prostatic hyperplasia (BPH) [6–8]. BPH has
been described as a common clinical syndrome in older
men characterized by bladder outlet obstruction, lower
urinary tract symptoms, and benign prostatic enlarge-
ment [9]. One quarter of men, ages 50 to 79 years, have a
bladder outlet obstruction and lower urinary tract symp-
toms according to the Olmsted County Study of Urinary
Symptoms and Health Status among Men (OCS) [10].
Technically, the diagnosis of BPH is based on histology,
but performing a biopsy is impractical. Instead, the clin-
ical syndrome, coupled with bother from symptoms, has
been used primarily in making BPH treatment decisions
[11].
Clinical practice guidelines disagree on serum crea-
tinine screening among men being evaluated for lower
urinary tract symptoms [11, 12]. The low prevalence of
chronic kidney disease in BPH clinical trials has been
a reason for recommending against serum creatinine
screening [11]. However, BPH clinical trials excluded
men without lower urinary tract symptoms, and were not
representative of the general community. Therefore, the
objective of this study was to examine the association be-
tween the clinical syndrome of BPH and risk of chronic
kidney disease in community-dwelling men.
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METHODS
Many of the details of this study have been published
previously [13]. Under institutional review board ap-
proval, a sampling frame of white men aged 40 to 79
years on January 1, 1990 in Olmsted County, Minnesota
was constructed using the resources of the Rochester
Epidemiology Project [14]. A random sample of 5135
white men were selected within age- (5 year groups) and
residence- (Rochester vs. balance of Olmsted County)
specific strata, and then evaluated for eligibility. Com-
munity medical records were screened to exclude men
with prostate surgery, prostate cancer, bladder cancer,
urethral stricture, neurogenic bladder, diabetes with doc-
umented end-organ damage, or other neurologic dis-
eases that could affect normal urinary function other
than BPH. After these exclusions, 3874 men were in-
vited to join the study, 2115 (55%) of whom participated.
Participants tended to be older or have a clinical his-
tory of BPH compared to nonparticipants [15]. These
subjects completed a questionnaire regarding lower uri-
nary tract symptom severity that was similar to the In-
ternational Prostate Symptom Score (IPSS) [16]. This
questionnaire also included medical history queries for
“diabetes,” “high blood pressure,” and “do you smoke
cigarettes now.” All participants had their peak urinary
flow rate measured by means of a portable uroflow meter
(Dantec Medical, Santa Clara, CA, USA).
Of the 2115 participants, 537 (25%) were randomly se-
lected for a detailed clinical exam, 476 (89%) of whom
participated. Clinical exams performed between June
1990 and July 1991 included height, weight, serum creati-
nine levels, serum prostate specific antigen (PSA) levels,
urine dipstick, uroflowmeter for peak flow rates, transrec-
tal sonographic imaging for prostate volume, and trans-
abdominal sonographic imaging for postvoid residual
urine volume. The prostate volume and postvoid resid-
ual were estimated from the anteroposterior, transverse,
and superoinferior diameters, using the formula for an
ellipsoid, p /6 (transverse × anteroposterior × superoin-
ferior) [17]. A standard urine dipstick measured protein-
uria and leukocyte esterase. Trace or higher leukocyte
esterase identified men with a possible urinary tract in-
fection, a potential confounder between BPH measures
and chronic kidney disease. This present study was lim-
ited to the clinical exam participants.
BPH measures were divided between three obstruction
measures (peak flow rates, postvoid residual, IPSS) and
two prostatic enlargement measures (prostate volume,
PSA). Elevated PSA in men without prostate cancer is a
strong predictor of prostatic enlargement [18]. IPSS mea-
sures are both bladder outlet obstruction–related (ob-
structive symptoms) [19] and detrusor instability–related
(irritative symptoms). Thus, individual analyses were
done for each of the obstructive and irritative symptom
queries of the questionnaire. BPH measures were also
dichotomized between normal and abnormal according
to standard cut points. Peak flow rate was dichotomized
as ≥15 mL/sec versus <15 mL/sec, IPSS as 0 to 7 (none-
mild) versus >7 (moderate-severe), residual urine vol-
ume as ≤100 mL versus >100 mL, prostate volume as
≤30 mL versus >30 mL, and PSA ≤1.4 ng/mL versus
>1.4 ng/mL. Two or more obstruction-related measures
(peak flow rate <15 mL/sec, IPSS >7, residual urine vol-
ume >100 mL) defined a bladder outlet obstruction. A
secondary analysis using continuous BPH measures (log-
transformed when appropriate) gave similar results, so
only dichotomized measures were reported.
Serum creatinine was measured by the modified ki-
netic rate Jaffe reaction method using a Hitachi 736
autoanalyzer (Hitachi, Ltd., Tokyo, Japan). Acutely ill
subjects had their clinic exam rescheduled for a later date,
such that all serum creatinine levels were likely to repre-
sent a stable renal function and not acute renal failure. A
serum creatinine level greater than or equal to 133 lmol/L
(1.5 mg/dL) was used as the definition of chronic kidney
disease for several reasons. First, the 97.5th percentile
for healthy men at the study laboratory was 124 lmol/L
(1.4 mg/dL). Second, using this definition allowed com-
parisons between this study and other BPH studies that
also used a serum creatinine cutoff. Third, the abbrevi-
ated Modification of Diet in Renal Disease (MDRD)
equation [20] underestimates GFR in healthy persons,
and may not be accurate for assessing GFR in the gen-
eral population [21]. However, a sensitivity analysis was
performed using the abbreviated MDRD equation in the
following form: estimated GFR = 186.3 × serum creati-
nine−1·154 × age−0·203. For the sensitivity analysis, chronic
kidney disease was defined by an estimated GFR<60 mL/
min/1.73m2 [20]. A secondary analysis was also per-
formed using urine dipstick protein trace or higher to
define CKD.
The distribution of BPH measures (peak urinary flow
rate, IPSS, residual urine volume, prostate volume, and
PSA) and comorbidities associated with kidney disease
(diabetes mellitus, hypertension, smoking, and leukocyte
esterase positive) were determined. Median and quar-
tile values of continuous variables and percentages of
dichotomized variables for exposures (BPH measures),
covariates (comorbidities), and outcomes (serum crea-
tinine) were calculated by chronic kidney disease status.
Comparisons were made using the rank sum or chi-square
test as appropriate.
Odds ratios for the outcome of chronic kidney dis-
ease were calculated using logistic regression models,
with each BPH measure as the exposure of interest.
Confidence intervals for odds ratios were calculated us-
ing the more conservative likelihood ratio method. Age
groups of 40 to 49 years (reference age group), 50 to 69
years, and 70 to 79 years were used for age adjustment.
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Table 1. Characteristics of study cohort by chronic kidney disease (CKD) status
CKD (N = 29) No CKD (N = 447)
Rank sum test
Median 1st Quartile 3rd Quartile Median 1st Quartile 3rd Quartile P value
Characteristics
Age years 59 46 73 55 47 63 0.13
Weight kg 83 76 95 86 77 96 0.52
Height cm 178 173 181 178 173 182 0.84
Serum creatinine lmol/L 133 133 141 97 88 115 <0.0001
GFR mL/min/1.73m2a 49 46 52 71 63 79 <0.0001
Body mass index kg/m2 27.4 24.6 28.9 27.0 25.0 30.1 0.52
CKD No CKD Chi-square P value
BPH measures
Slow stream (peak urinary flow <15 mL/sec) 18 (62%) 158 (35%) 0.0040
Lower urinary tract symptoms (IPSS >7)b 17 (59%) 145 (33%) 0.0041
Chronic retention (postvoid residual >100 mL) 5 (17%) 27 (6%) 0.020
Bladder outlet obstructionc 14 (48%) 90 (20%) 0.0004
Enlarged prostate (volume >30 mL) 10 (34%) 170 (38%) 0.68
Enlarged prostate (PSA >1.4 ng/mL) 11 (38%) 131 (29%) 0.33
Comorbidities
Diabetes (per questionnaire) 3 (10%) 19 (4%) 0.13
Hypertension (per questionnaire) 12 (41%) 94 (21%) 0.012
Leukocyte esterase positive on dipstick 3 (10%) 18 (4%) 0.11
Current smoker 5 (18%) 57 (13%) 0.45
Combined comorbidityd 19 (66%) 158 (35%) 0.0012
aEstimated glomerular filtration rate using the abbreviated MDRD equation.
bIPSS, International Prostate Symptom Score.
cAt least 2 of 3: peak flow rate <15 mL/sec, IPSS >7, or postvoid residual >100 mL.
dPresence of either diabetes, hypertension, leukocyte esterase positive, or current smoker.
Adjustment by age as a continuous variable gave sim-
ilar results and was not reported. A comorbidity risk
factor was defined by the presence of any of the fol-
lowing: diabetes, hypertension, leukocyte esterase pos-
itive, or smoking. Both age groups and comorbidity
risk factors were included in multivariable models. The
prevalence of chronic kidney disease was stratified by
number of obstruction measures (peak flow rate <15 mL/
sec, IPSS >7, postvoid residual <100 mL) and num-
ber of prostatic enlargement measures (prostate volume
>30 mL, PSA >1.4 ng/mL). The prevalence of chronic
kidney disease by number of obstruction measures and by
number of prostatic enlargement measures was assessed
with a Mantel-Haenszel chi-square test.
For all analyses, a P value less than 0.05 was considered
statistically significant. All analyses were conducted using
SAS version 8.2 (SAS Institute, Cary, NC, USA).
RESULTS
Overall, 29 (6%) of the 476 men had chronic kidney
disease as defined by a serum creatinine ≥133 lmol/L
(1.5 mg/dL). Table 1 presents the demographics, BPH
measures, and comorbidity measures by chronic kidney
disease status. Men with chronic kidney disease were
more likely to have a slow urinary stream (P < .01),
moderate-severe lower urinary tract symptoms (P < .01),
and chronic urinary retention (P < .05). There was also
an increased prevalence of diabetes mellitus, hyperten-
sion, and leukocyte esterase positive dipstick among men
with chronic kidney disease. Four men were identified as
having prostate cancer, none of which had chronic kid-
ney disease. Exclusion of these men did not change the
results.
Table 2 shows the unadjusted, age-adjusted, and age-
and comorbidity-adjusted odds ratios of chronic kidney
disease. Peak urinary flow <15 mL/sec (slow stream) and
IPSS>7 (moderate-severe lower urinary tract symptoms)
were associated with an increased risk of chronic kid-
ney disease (age- and comorbidity-adjusted, P < .05).
Postvoid residual >100 mL (chronic urinary retention)
showed an increased risk of chronic kidney disease, but
was not statistically significant (age- and comorbidity-
adjusted, P = .16). Patients with bladder outlet obstruc-
tion had an increased risk of chronic kidney disease
(age- and comorbidity-adjusted, P < .05). Prostate vol-
ume and PSA were not associated with chronic kidney
disease. Of the individual comorbidity measures, only hy-
pertension was significantly associated with an increased
risk of chronic kidney disease (age-adjusted, P < .05). Di-
abetes mellitus, leukocyte esterase positive, and smoking
all trended toward an increased risk of chronic kidney dis-
ease, but were not statistically significant. When all pre-
dictors (BPH measures, comorbidities, and age groups)
were combined in the same multivariable model, peak
urinary flow <15 mL/sec (OR = 2.63, 95% CI 1.08–6.58)
remained statistically significant, but IPSS >7 (OR =
2.17, 95% CI 0.94–5.09) and postvoid residual >100 mL
(OR = 2.48, 95% CI 0.72–7.33) were only borderline sta-
tistically significant.
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Table 2. Association between chronic kidney disease (serum creatinine ≥133 lmol/L) and benign prostatic hyperplasia (BPH) measures
Unadjusted Age and comorbidity
Potential risk factor odds ratio (OR) Age-adjusteda OR adjustedb OR
BPH measure
Peak flow rate <15 mL/sec 2.98 (1.39, 6.67) 2.74 (1.23, 6.35) 2.96 (1.30, 7.01)
IPSSc >7 2.94 (1.38, 6.47) 2.82 (1.29, 6.34) 2.91 (1.32, 6.62)
Residual urine volume >100 mL 3.23 (1.03, 8.56) 2.30 (0.69, 6.49) 2.28 (0.66, 6.68)
Bladder outlet obstructiond 3.69 (1.70, 7.96) 3.40 (1.49, 7.73) 3.57 (1.54, 8.28)
Prostate volume >30 mL 0.85 (0.37, 1.82) 0.60 (0.24, 1.45) 0.56 (0.22, 1.37)
PSA >1.4 ng/mL 1.47 (0.66, 3.16) 1.09 (0.44, 2.60) 1.17 (0.47, 2.81)
Comorbidity measure
Hypertensione 2.63 (1.19, 5.66) 2.39 (1.06, 5.24) –
Diabetes mellituse 2.59 (0.58, 8.25) 2.13 (0.46, 7.14) –
Leukocyte esterase positive 2.74 (0.61, 8.76) 2.21 (0.48, 7.44) –
Current smokere 1.47 (0.48, 3.73) 1.59 (0.51, 4.13) –
Any comorbidity risk factor 3.46 (1.60, 7.93) 3.07 (1.40, 7.11) –
aAge-adjusted using age groups: 40 to 49 (reference age group), 50 to 69, and 70 to 79 years.
bAdjusted for age groups and presence of any comorbidity risk factor (diabetes mellitus, hypertension, leukocyte esterase positive, or current smoker).
cIPSS, International Prostate Symptom Score.
dAt least 2 of 3: peak flow rate <15 mL/sec, IPSS >7, or postvoid residual >100 mL.
eHypertension, diabetes mellitus, and smoking status per self-reported questionnaire; diabetics with known end-organ damage were excluded during sampling.
Table 3. Association between chronic kidney disease (serum creatinine ≥133 lmol/L) and obstructive or irritative lower urinary tract symptoms
Unadjusted odds ratio Age-adjustedb Age and comorbidity
Potential risk factora (OR) (95% CI) OR (95% CI) adjustedc OR (95% CI)
Obstructive symptom score 2.42 (1.11, 5.19) 2.36 (1.06, 5.15) 2.74 (1.22, 6.10)
Feeling your bladder was not empty after urinating 1.80 (0.73, 4.06) 1.76 (0.70, 4.03) 1.93 (0.76, 4.49)
Stopping or starting again when urinating 1.62 (0.68, 3.57) 1.59 (0.66, 3.59) 1.93 (0.78, 4.48)
Straining or pushing during urination 2.52 (0.96, 5.94) 2.50 (0.93, 5.99) 2.74 (1.00, 6.76)
Smaller size or weaker force of your urinary stream 2.22 (1.04, 4.78) 2.19 (1.01, 4.79) 2.46 (1.11, 5.49)
Irritative symptom score 2.11 (0.99, 4.64) 1.93 (0.90, 4.28) 1.83 (0.84, 4.09)
Having to urinate more frequently then every 2 hours during the day 1.45 (0.66, 3.10) 1.34 (0.60, 2.89) 1.29 (0.58, 2.82)
Feeling you can’t wait to urinate 2.00 (0.94, 4.33) 1.83 (0.85, 4.01) 1.98 (0.91, 4.39)
Getting up to urinate during the night 3.00 (1.35, 6.47) 2.54 (1.10, 5.69) 2.29 (0.97, 5.21)
aCut point definitions for risk factors: obstructive symptom score >4, irritative symptom score >3, individual symptom scores >1 [16].
bAdjusted using age groups: 40 to 49 (reference age group), 50 to 69, and 70 to 79 years.
cAdjusted for age groups and comorbidity risk factor (diabetes, hypertension, leukocyte esterase positive, or current smoker).
Table 3 shows the unadjusted, age-adjusted, and age-
and comorbidity-adjusted odds ratio for chronic kidney
disease by each IPSS question. The chronic kid-
ney disease risk with obstructive symptoms (age- and
comorbidity-adjusted OR = 2.74, P < .05) was slightly
stronger than the risk with irritative symptoms (age-
and comorbidity-adjusted OR = 1.83, P = .13). In addi-
tion, the two individual symptoms that directly describe
an obstructive process: straining (age- and comorbidity-
adjusted OR = 2.74, P = .05) and weak stream (age-
and comorbidity-adjusted OR = 2.46, P < .05), trended
toward a higher risk of chronic kidney disease than the
other individual symptoms.
Figure 1 presents the prevalence of chronic kidney dis-
ease by number of obstruction measures. There was a
significant graded relationship between the number of
obstruction measures and the corresponding prevalence
of chronic kidney disease (P < .0001, Mantel-Haenszel
chi-square). There was no relationship between number
of prostatic enlargement measures and the corresponding
prevalence of chronic kidney disease (P = .74, Mantel-
Haenszel chi-square).
The results were similar when chronic kidney disease
was defined by an estimated GFR less than 60 mL/min/
1.73m2. By this definition, 101 men (21%) had chronic
kidney disease. The age- and comorbidity-adjusted odds
ratio of chronic kidney disease was 2.30 (95% CI 1.44–
3.69) for peak flow rate <15 mL/sec, 1.49 (95% CI 0.93–
2.38) for IPSS >7, 2.65 (95% CI 1.20–5.72) for resid-
ual urine volume >100 mL, 1.01 (95% CI 0.61–1.68) for
prostate volume >30 mL, and 1.45 (95% CI 0.87–2.40)
for PSA >1.4 ng/mL. The age- and comorbidity-adjusted
odds ratio of chronic kidney disease for patients with
two or three obstruction measures compared to those
with zero or one measures was 2.54 (95% CI 1.52–4.22).
There was a significant graded relationship between the
number of obstruction measures and the corresponding
prevalence of chronic kidney disease (P < .0001, Mantel-
Haenszel chi-square).
An association between BPH measures and urine
dipstick protein (trace or higher) was not apparent.
Twenty-seven of 476 men (6%) had proteinuria, only
two of which had a serum creatinine ≥133 lmol/L (1.5
mg/dL). The age- and comorbidity-adjusted odds ratio of
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Fig. 1. Prevalence of chronic kidney disease (SCr ≥133 lmol/L) by
number of bladder outlet obstruction–related measures (P < .0001,
Mantel-Haenszel chi-square). Three different obstruction-related mea-
sures were used: International Prostate Symptom Score >7, peak uri-
nary flow rate <15 mL/sec, and residual urine volume >100 mL.
proteinuria was 1.65 (95% CI 0.72–3.90) for peak flow
rate <15 mL/sec, 0.98 (95% CI 0.41–2.21) for IPSS >7,
1.32 (95% CI 0.35–4.98) for residual urine volume >100
mL, 1.02 (95% CI 0.43–2.39) for prostate volume >30
mL, and 0.98 (95% CI 0.40–2.30) for PSA >1.4 ng/mL.
DISCUSSION
Our study identified a positive and significant cross-
sectional relationship between bladder outlet obstruction
and chronic kidney disease in community-dwelling men,
although the absolute risk seemed to be modest. This
association was present when chronic kidney disease was
identified by an elevated serum creatinine, but not by dip-
stick proteinuria. An association between prostatic en-
largement and chronic kidney disease was not present.
These relationships were independent of age or other
risk factors associated with kidney disease: diabetes, hy-
pertension, leukocyte esterase positive dipstick (possible
urinary tract infection), and smoking. These associations
were based on three different measures related to bladder
outlet obstruction (all commonly used in clinical trials)
and two different measures of the prostatic enlargement.
A sensitivity analysis using the MDRD equation to define
chronic kidney disease gave similar results.
Analyses of individual symptoms as queried in the
IPSS provided additional support that bladder out-
let obstruction–related symptoms are risk factors for
chronic kidney disease. Obstructive symptoms were more
strongly associated with chronic kidney disease than ir-
ritative symptoms. This may be important because pre-
dominantly irritative symptoms motivate men to present
for prostate surgery [22].
Previous studies have suggested an association be-
tween BPH and chronic kidney disease but have had
more study design limitations. A community-based study
of men age 50 years or older found a 2.4% prevalence
of self-reported renal failure related to a prostate con-
dition (9% reported renal failure from any cause) [23].
Most other studies have been referral-based in men
presenting to a urologist. Because some of these men
may have had acute renal failure from acute urinary re-
tention, inferences about chronic kidney disease were
limited. One study found a 7.7% prevalence of renal fail-
ure in men presenting for prostate surgery compared to
a 3.7% prevalence in age-matched men presenting for
nonprostate surgery [24]. Many studies of men with renal
failure and bladder outlet obstruction show improvement
in renal function in the follow-up after prostate surgery
[25–27]. Case reports have also shown dialysis-dependent
patients recover renal function up to a year after having
prostate surgery [28].
The low occurrence of chronic kidney disease in BPH
clinical trials should not be used to infer a weak associ-
ation between these two disease processes. First, some
clinical trials attempted to assign a single etiology (i.e.,
BPH vs. diabetes) to chronic kidney disease [29] when
chronic kidney disease often has multiple etiologies [2–4].
Second, high serum creatinine cutoffs [up to 265 lmol/L
(3.0 mg/dL)] were often used to identify cases of chronic
kidney disease [30] and will miss less advanced disease.
Third, men without lower urinary tract symptoms or di-
minished peak urinary flow rates did not meet the inclu-
sion criteria for these trials [29]. Thus, the full spectrum
of BPH disease was not represented. Finally, due to the
healthy volunteer effect in clinical trials, incident chronic
kidney disease may have been missed during the short
duration of follow-up.
Chronic kidney disease from BPH has been identified
as a very rare event in prior epidemiologic studies [9]. For
example, a study by Gerber et al looked at 246 consecu-
tive men that presented to a urologist for evaluation of
lower urinary tract symptoms, 26 (11%) of whom had a
serum creatinine ≥133 lmol/L (1.5 mg/dL) [31]. Chronic
kidney disease was not associated with lower urinary tract
symptoms in the Gerber et al study: odds ratio = 0.76
(95% CI 0.32–1.80), but was in this study: odds ratio =
2.94 (95% CI 1.38–6.47). The odds ratios did not change
with age and comorbidity adjustment in either study, so
a stratified analysis was done to clarify the discrepancy.
The prevalence of chronic kidney disease among men
with moderate-severe symptoms (IPSS >7) in this study
was 10.5%, similar to the 9.8% in the study by Gerber
et al. However, the prevalence of chronic kidney disease
among men with none-mild symptoms (IPSS ≤7) in this
study was 3.8%, much less than the 12.5% in the study
by Gerber et al. This would suggest that men with low
symptom scores who present to a urologist may be dif-
ferent from men with low symptom scores in the general
community.
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A possible mechanistic pathway by which BPH leads to
chronic kidney disease could be an obstructive uropathy
at the uretero-vesicular junction [32]. Chronic urinary
retention leads to bladder wall thickening with trabec-
ulations via smooth muscle hypertrophy and connec-
tive tissue infiltrates [25]. Men with chronic urinary
retention often have increased bladder pressures, de-
creased bladder compliance, and detrusor instability, all
of which have been directly associated with renal fail-
ure [6–8]. The bladder wall thickening that leads to
a decline in bladder compliance can result in a func-
tional or mechanical obstruction at the ureterovesic-
ular junction [32]. However, evaluation for upper
tract dilatation (hydronephrosis) was not done in this
study.
Potential limitations of our study should be noted. With
a cross-sectional study design, a temporal relationship
cannot be determined. It is conceivable that chronic kid-
ney disease could be a risk factor for BPH or detrusor
weakness. With only 29 cases of an elevated serum creati-
nine, some associations were only borderline statistically
significant, particularly with multivariable adjustment.
Serum creatinine levels and dipstick proteinuria were
used to define chronic kidney disease instead of measured
glomerular filtration rate and urinary albumin-creatinine
ratios. Though serum creatinine is a widely used marker
of renal function in epidemiologic studies, muscle mass
and protein intake can also affect serum creatinine levels.
A cohort study is needed to assess longitudinal changes
in serum creatinine with respect to BPH measures and to
clarify the temporal relationship. The standard dipstick
may lack adequate sensitivity to identify an association
between albuminuria and BPH. Because hypertension
and diabetes mellitus were self-reported, they could still
be a source of residual confounding. Finally, the commu-
nity sample was white and predominantly middle class; in-
ferences to other racial and socioeconomic groups should
be made with caution.
CONCLUSION
This study demonstrated an association between blad-
der outlet obstruction and chronic kidney disease in men.
This finding has potential importance for clinical practice
and public health because benign prostatic hyperplasia
and chronic kidney disease are common in older men.
Obtaining a serum creatinine in men presenting for an
evaluation of BPH may be reasonable to guide further
evaluation or treatment decisions. A bladder outlet ob-
struction should also be considered in the differential
diagnosis of an older man presenting with an elevated
serum creatinine, even if the prostate size is normal. Fu-
ture studies are needed to assess whether treatment of
a bladder outlet obstructive will impact progression of
chronic kidney disease.
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